Company / R&D Expense
Valion Bio, Inc. R&D Expense History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$1.7M
FY2024
5-year range
$878.0K / $1.7M
FY2022-FY2024
Trend
-4.3%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $878,000 to $2M over the past 2 years.
Based on SEC 10-K filings.
$2M in FY2024.
Improved from $878,000 to $2M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, r&d expense decreased 4.3% year-over-year.
Company context
Key Data Points
- Altman Z-Score -10.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $1.7M | -4.3% |
| FY2023 | $1.7M | +97.0% |
| FY2022 | $878.0K | - |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026